vs
Avantor, Inc.（AVTR）与Cytek Biosciences, Inc.（CTKB）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是Cytek Biosciences, Inc.的26.8倍（$1.7B vs $62.1M）。Avantor, Inc.净利率更高（3.1% vs -70.9%，领先74.1%）。Cytek Biosciences, Inc.同比增速更快（8.1% vs -1.4%）。Avantor, Inc.自由现金流更多（$117.2M vs $-1.8M）。过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
AVTR vs CTKB — 直观对比
营收规模更大
AVTR
是对方的26.8倍
$62.1M
营收增速更快
CTKB
高出9.5%
-1.4%
净利率更高
AVTR
高出74.1%
-70.9%
自由现金流更多
AVTR
多$119.0M
$-1.8M
两年增速更快
CTKB
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $62.1M |
| 净利润 | $52.4M | $-44.1M |
| 毛利率 | 31.5% | 52.9% |
| 营业利润率 | 7.6% | -9.0% |
| 净利率 | 3.1% | -70.9% |
| 营收同比 | -1.4% | 8.1% |
| 净利润同比 | -89.5% | -557.1% |
| 每股收益（稀释后） | $0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRCTKB
| Q4 25 | $1.7B | $62.1M | ||
| Q3 25 | $1.6B | $52.3M | ||
| Q2 25 | $1.7B | $45.6M | ||
| Q1 25 | $1.6B | $41.5M | ||
| Q4 24 | $1.7B | $57.5M | ||
| Q3 24 | $1.7B | $51.5M | ||
| Q2 24 | $1.7B | $46.6M | ||
| Q1 24 | $1.7B | $44.9M |
净利润AVTRCTKB
| Q4 25 | $52.4M | $-44.1M | ||
| Q3 25 | $-711.8M | $-5.5M | ||
| Q2 25 | $64.7M | $-5.6M | ||
| Q1 25 | $64.5M | $-11.4M | ||
| Q4 24 | $500.4M | $9.6M | ||
| Q3 24 | $57.8M | $941.0K | ||
| Q2 24 | $92.9M | $-10.4M | ||
| Q1 24 | $60.4M | $-6.2M |
毛利率AVTRCTKB
| Q4 25 | 31.5% | 52.9% | ||
| Q3 25 | 32.4% | 52.7% | ||
| Q2 25 | 32.9% | 52.3% | ||
| Q1 25 | 33.8% | 48.6% | ||
| Q4 24 | 33.4% | 58.5% | ||
| Q3 24 | 32.9% | 56.3% | ||
| Q2 24 | 34.1% | 54.6% | ||
| Q1 24 | 34.0% | 51.3% |
营业利润率AVTRCTKB
| Q4 25 | 7.6% | -9.0% | ||
| Q3 25 | -40.0% | -17.6% | ||
| Q2 25 | 7.7% | -23.3% | ||
| Q1 25 | 9.3% | -36.1% | ||
| Q4 24 | 37.8% | 5.2% | ||
| Q3 24 | 7.3% | -8.2% | ||
| Q2 24 | 10.3% | -18.3% | ||
| Q1 24 | 8.7% | -23.9% |
净利率AVTRCTKB
| Q4 25 | 3.1% | -70.9% | ||
| Q3 25 | -43.8% | -10.5% | ||
| Q2 25 | 3.8% | -12.2% | ||
| Q1 25 | 4.1% | -27.5% | ||
| Q4 24 | 29.7% | 16.8% | ||
| Q3 24 | 3.4% | 1.8% | ||
| Q2 24 | 5.5% | -22.4% | ||
| Q1 24 | 3.6% | -13.8% |
每股收益（稀释后）AVTRCTKB
| Q4 25 | $0.08 | — | ||
| Q3 25 | $-1.04 | — | ||
| Q2 25 | $0.09 | — | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $0.73 | — | ||
| Q3 24 | $0.08 | — | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $90.9M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $341.7M |
| 总资产 | $11.8B | $461.5M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRCTKB
| Q4 25 | $365.4M | $90.9M | ||
| Q3 25 | $251.9M | $93.3M | ||
| Q2 25 | $449.4M | $75.5M | ||
| Q1 25 | $315.7M | $95.3M | ||
| Q4 24 | $261.9M | $98.7M | ||
| Q3 24 | $285.3M | $162.3M | ||
| Q2 24 | $272.6M | $177.9M | ||
| Q1 24 | $234.9M | $168.8M |
总债务AVTRCTKB
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRCTKB
| Q4 25 | $5.6B | $341.7M | ||
| Q3 25 | $5.6B | $378.6M | ||
| Q2 25 | $6.3B | $377.6M | ||
| Q1 25 | $6.1B | $379.6M | ||
| Q4 24 | $6.0B | $395.7M | ||
| Q3 24 | $5.6B | $385.5M | ||
| Q2 24 | $5.4B | $389.1M | ||
| Q1 24 | $5.3B | $392.6M |
总资产AVTRCTKB
| Q4 25 | $11.8B | $461.5M | ||
| Q3 25 | $11.7B | $494.9M | ||
| Q2 25 | $12.8B | $493.3M | ||
| Q1 25 | $12.3B | $482.6M | ||
| Q4 24 | $12.1B | $499.5M | ||
| Q3 24 | $12.8B | $491.2M | ||
| Q2 24 | $12.7B | $483.7M | ||
| Q1 24 | $12.8B | $492.1M |
负债/权益比AVTRCTKB
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-771.0K |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-1.8M |
| 自由现金流率自由现金流/营收 | 7.0% | -2.9% |
| 资本支出强度资本支出/营收 | 2.1% | 1.6% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $-8.8M |
8季度趋势，按日历期对齐
经营现金流AVTRCTKB
| Q4 25 | $152.7M | $-771.0K | ||
| Q3 25 | $207.4M | $-3.9M | ||
| Q2 25 | $154.4M | $108.0K | ||
| Q1 25 | $109.3M | $-125.0K | ||
| Q4 24 | $173.3M | $2.0M | ||
| Q3 24 | $244.8M | $13.2M | ||
| Q2 24 | $281.1M | $6.2M | ||
| Q1 24 | $141.6M | $4.0M |
自由现金流AVTRCTKB
| Q4 25 | $117.2M | $-1.8M | ||
| Q3 25 | $171.7M | $-4.6M | ||
| Q2 25 | $124.8M | $-1.5M | ||
| Q1 25 | $81.3M | $-974.0K | ||
| Q4 24 | $145.8M | $1.1M | ||
| Q3 24 | $204.0M | $12.2M | ||
| Q2 24 | $235.3M | $5.2M | ||
| Q1 24 | $106.9M | $3.4M |
自由现金流率AVTRCTKB
| Q4 25 | 7.0% | -2.9% | ||
| Q3 25 | 10.6% | -8.7% | ||
| Q2 25 | 7.4% | -3.2% | ||
| Q1 25 | 5.1% | -2.3% | ||
| Q4 24 | 8.6% | 1.9% | ||
| Q3 24 | 11.9% | 23.7% | ||
| Q2 24 | 13.8% | 11.0% | ||
| Q1 24 | 6.4% | 7.6% |
资本支出强度AVTRCTKB
| Q4 25 | 2.1% | 1.6% | ||
| Q3 25 | 2.2% | 1.3% | ||
| Q2 25 | 1.8% | 3.5% | ||
| Q1 25 | 1.8% | 2.0% | ||
| Q4 24 | 1.6% | 1.6% | ||
| Q3 24 | 2.4% | 2.0% | ||
| Q2 24 | 2.7% | 2.3% | ||
| Q1 24 | 2.1% | 1.3% |
现金转化率AVTRCTKB
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | 0.21× | ||
| Q3 24 | 4.24× | 14.05× | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
